PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 28 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 28 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
- 28 Feb 2019 Status changed from recruiting to active, no longer recruiting.